Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. Zacks Investment Research currently has $1.00 price objective on the stock.
According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “
SINO BIOPHARMACEUT HKD0.025 (SBMFF) opened at 0.988 on Thursday. The stock has a market cap of $7.32 billion and a P/E ratio of 25.333. The firm’s 50-day moving average is $0.90 and its 200-day moving average is $0.83. SINO BIOPHARMACEUT HKD0.025 has a 52-week low of $0.72 and a 52-week high of $0.99.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with MarketBeat.com's FREE daily email newsletter.